,id,ticker,title,category,content,date,provider,url,article_id
1344,222859,CLSN,Alexion To Start Pivotal Study On Ultomiris For ALS In Q1,opinion,"Alexion Pharmaceuticals Inc    NASDAQ ALXN   announced plans to start a pivotal phase III study to evaluate its long acting C5 complement inhibitor  Ultomiris  ravulizumab   in a new indication   amyotrophic lateral sclerosis  ALS   The study will be called CHAMPION ALS  n 350  and evaluate the efficacy and safety of Ultomiris across a broad ALS patient population  ALS is a neurological disorder characterized by progressive degeneration of nerve cells in the brain and the spinal cord  which control muscles throughout the body  
Alexion submitted an investigational new drug application  IND  for Ultomiris in ALS to the FDA in the fourth quarter of 2019  The company plans to initiate the phase III study in the first quarter of 2020 
The patients in the study will be randomized on a 2 1 basis to receive Ultomiris or placebo every eight weeks after an initial loading dose and may continue to receive their existing standard of care treatment for ALS  After 50 weeks  all patients will receive Ultomiris in a two year  open label extension phase of the study  The study will be conducted at about 90 sites across North America  Europe and the Asia Pacific 
Alexion s share price has gained 1  in the past year against the  s decline of 1 8  

 
We remind investors that Ultomiris is approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  PNH  to be administered every eight weeks  The drug is also approved in the United States for the treatment of atypical hemolytic uremic syndrome  aHUS  in adults and children one month and older 
Ultomiris recorded sales of  168 7 million in the nine months ended Sep 30  2019 
The label expansion of the drug into additional indications will boost sales further Alexion Pharmaceuticals  Inc  Price
 

    
Zacks Rank   Other Stocks to Consider
Alexion is currently a Zacks Rank  1  Strong Buy  stock 
A few similar ranked stocks in the biotech sector are Anavex Life Sciences Corp    NASDAQ AVXL    ASLAN Pharmaceuticals Ltd    NASDAQ ASLN   and Celsion Corp    NASDAQ CLSN    You can see  
Anavex s loss per share estimates have narrowed from  64 cents to 48 cents for 2019 and from 67 cents to 42 cents for 2020 in the past 90 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 0 57   on average 
ASLAN s loss per share estimates have narrowed from 69 cents to 67 cents for 2019 and from 62 cents to 61 cents for 2020 in the past 90 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 24 65   on average 
Celsion s loss per share estimates have narrowed from  1 00 to 94 cents for 2019 and from 77 cents to 66 cents for 2020 in the past 90 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 51 11   on average 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0  and even  158 9   This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/alexion-to-start-pivotal-study-on-ultomiris-for-als-in-q1-200499094,200499094
1352,222867,CLSN,IVERIC Bio s  ISEE  Q1 Loss Narrows  Gene Therapy In Focus,opinion,"IVERIC bio   NASDAQ ISEE   reported loss of 30 cents per share for first quarter 2019  narrower than the Zacks Consensus Estimate as well as the year ago loss of 36 cents 
With no approved products in its portfolio  IVERIC bio derives revenues from milestone and other payments under collaborations  However  there were no such revenues in the quarter 
On Apr 16  the company announced that it has changed its name from Ophthotech Corporation to IVERIC bio  The change in name of the company was part of the transition strategy to focus primarily on developing gene therapies to treat orphan inherited retinal diseases   IRD    The company s ticker was also changed from OPHT to ISEE 
Shares of IVERIC bio have increased 19 2  so far this year compared with the  s rise of 3 2  

Quarter in Detail
Research and development expenses in the first quarter remained flat year over year at  7 7 million  The increase in expenses related to gene therapy programs was offset by lower costs associated with the Zimura programs 
General and administrative expenses decreased 1 8  from the year ago period to  5 5 million due to lower infrastructure and operational costs 
Cash Balance
IVERIC bio s cash balance was  116 6 million as of Mar 31  2019 compared with  131 2 million on Dec 31  2018 
The company expects cash and cash equivalents in the range of  80  85 million in 2019  taking into account the impact of preclinical development  collaborative research programs for gene therapies and continuation of Zimura development 
Pipeline and Other Updates
With the change of the company s name to IVERIC bio  it is now primarily focused on developing gene therapy programs  The company expects to initiate clinical studies on gene therapy candidates in 2020 and 2021 to evaluate them as a treatment for BEST1 related retinal diseases and Leber congenital amaurosis type 10  LCA10  
The company s C5 complement inhibitor candidate  Zimura  is being evaluated in several mid stage clinical studies for the treatment of dry and wet AMD  Stargardt disease and geographic atrophy  The company remains on track to announce top line data from the phase IIb study on the candidate in geographic atrophy patients in the fourth quarter of 2019 
Zacks Rank   Stocks to Consider
IVERIC bio currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the pharmaceutical sector include Celsion Corp    NASDAQ CLSN    Fibrocell Science Inc   NASDAQ FCSC   and Editas Medicine  Inc    NASDAQ EDIT    While Celsion and Fibrocell sport a Zacks Rank  1  Strong Buy   Editas carries a Zacks Rank  2  Buy   You can see  
Celsion s loss estimates narrowed from 94 cents to 78 cents for both 2019 and 2020 over the past 60 days 
Fibrocell s loss estimates narrowed from  2 68 to  1 15 for 2019 and from  2 55 to 97 cents for 2020 over the past 60 days 
Editas  loss estimates narrowed from  2 74 to  2 68 for 2019 and from  3 10 to  3 01 for 2020 over the past 60 days 
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities 
These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/iveric-bios-isee-q1-loss-narrows-gene-therapy-in-focus-200419751,200419751
1353,222868,CLSN,Puma Biotech  PBYI  Q1 Earnings Top  Nerlynx Disappoints,opinion,"Puma Biotechnology  Inc    NASDAQ PBYI   incurred a loss of 26 cents per share for the first quarter of 2019  narrower than the Zacks Consensus Estimate of a loss of 69 cents as well as the year ago loss of 65 cents Total revenues consist of both net product revenues from the sales of Nerlynx  neratinib  and the company s license revenues  In the first quarter of 2019  total revenues came in at  99 1 million  comprising  45 6 million of product revenues from Nerlynx and  53 5 million of license revenues  Moreover  sales beat the Zacks Consensus Estimate of  65 0 million in the reported quarter and were also higher than the year ago figure of  66 5 million However  product sales were lower than management s expectations  which resulted in a sharp decline in the stock price in after hours trading  Shares of Puma Biotech crashed 32 5  in after hours trading following the earnings release on Thursday  However  the stock has gained 47 5  this year so far  outperforming the  s increase of 3 2  Sales of Nerlynx  Puma Biotech s only marketed drug  were down 25 4  on a sequential basis  Alan H  Auerbach  chief executive officer  CEO  of Puma Biotech attributed the disappointing performance to higher number of patients discontinuing treatment with Nerlynx  Also  an increase in expenses charged against gross revenues hurt sales in the quarter Nerlynx is indicated for extended adjuvant treatment of HER2 positive early stage breast cancer in patients  previously treated with Roche s   OTC RHHBY   Herceptin based adjuvant therapy  It was approved in the EU last September Total operating costs in the quarter were  89 2 million  up 0 8  year over year Research and development  R D  expenses were  35 7 million  down 23 9  from the year ago period owing to lower clinical study costs and stock based compensation expenses Selling  general and administrative expenses increased 24 3  year over year to  45 5 million  primarily due to higher professional fees  stock based compensation expenses and other costs As of Mar 31  2019  Puma Biotech had cash and cash equivalents of  48 8 million compared with  108 4 million as of Dec 31  2018 Other UpdatesSeveral further studies on Nerlynx targeting different types of breast cancer patient populations and in earlier line settings are currently underway  The drug s label expansion will allow it to treat and access an expanded patient population  Notably  last December  Puma Biotech announced positive top line results from the phase III NALA study  evaluating Nerlynx for the treatment of third line HER2 positive metastatic breast cancer Apart from the HER2 positive breast cancer indication  the company believes that neratinib holds potential for the treatment of several other cancers as well  including NSCLC and other tumor types that over express or have a mutation in HER2 Last month  Puma Biotech added two cohorts to the phase II SUMMIT basket study on Nerlynx  which is currently being conducted for treating solid tumors in patients with activating EGFR  HER2 or HER4 mutations  Puma Biotech plans to report data from the SUMMIT study in the second half of 2019 and expects to meet with the FDA to discuss the regulatory strategy for the SUMMIT study in the summer of 2019 Last month  the company out licensed exclusive rights to develop commercialize Nerlynx in Europe and across parts of Africa to French pharmaceutical company  Pierre Fabre  In January  it out licensed commercialization rights in Canada to Knight Therapeutics Puma Biotechnology  Inc  Price and Consensus
     
Zacks Rank   Stocks to ConsiderPuma Biotech currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the biotech sector include Celsion Corporation   NASDAQ CLSN   and Fibrocell Science Inc   NASDAQ FCSC    both sporting a Zacks Rank  1  Strong Buy   You can see  Celsion s loss estimates narrowed from 94 cents to 78 cents for both 2019 and 2020 over the past 60 days  Its shares have risen 53 9  this year so far Fibrocell s loss estimates narrowed from  2 68 to  1 15 for 2019 and from  2 55 to 97 cents for 2020 over the past 60 days  The stock has gone up 50  this year so far Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 7 stocks to watch  The report is only available for a limited time ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/puma-biotech-pbyi-q1-earnings-top-nerlynx-disappoints-200420132,200420132
1354,222869,CLSN,Spectrum Pharma  SPPI  Q1 Earnings Lag Estimates  Revenues Nil,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   incurred adjusted loss of 27 cents per share in the first quarter of 2019  wider than the Zacks Consensus Estimate of a loss of 23 cents  However  the loss was in line with the year ago quarter During the quarter  the company completed the sale of its marketed portfolio to privately held Acrotech Biopharma for an upfront payment of  158 8 million  The company is also eligible to receive additional regulatory and sales based milestone payments up to  140 million  With no marketed products  the company did not record any revenues in the first quarter  The Zacks Consensus Estimate was pegged at  20 45 million Spectrum Pharma s shares have increased 6 5  so far this year compared with the  s rise of 8 8  Quarter in DetailAdjusted research   development  R D  expenses were  20 4 million  up 60 5  from the year ago quarter In March  Spectrum Pharma withdrew the biologics license application   BLA   for Rolontis  The company had stated that the time required for gathering the additional manufacturing related data as requested by the FDA was unlikely to be completed within the review period which ended on Mar 29  The company will re submit the BLA as soon as possible Adjusted selling  general and administrative  SG A  spending was down 25 5  to  10 7 million Pipeline UpdateSpectrum Pharma is developing its pipeline candidates  poziotinib  as monotherapy or in combination with other drugs for the treatment of lung cancer and breast cancer  A phase II study   ZENITH20   is evaluating poziotinib in previously treated non small cell lung cancer   NSCLC   patients with an exon 20 mutation in EGFR or HER2  Data from EGFR cohort is expected in the fourth quarter of 2019  Enrollment in the HER2 cohort is expected to be completed in the fourth quarter as well Concurrent with the earnings release  the company announced an asset purchase and license agreement with privately held ImmunGene to acquire a novel immuno oncology platform and two early stage assets  The acquired platform  Focused Interferon Therapeutics   FIT    has potential for broad application in oncology  The two assets  antibody interferon fusion molecules  have been developed using the FIT platform One of the assets  targeting CD20  is in phase I development for treating relapsed or refractory non Hodgkin lymphoma  including diffuse large b cell lymphoma  Another candidate  targeting GRP94  has potential for treating both solid and hematologic malignancies Spectrum Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderSpectrum Pharma currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharmaceutical sector include Celsion Corporation   NASDAQ CLSN    Fibrocell Science Inc   NASDAQ FCSC   and Editas Medicine  Inc    NASDAQ EDIT    While Celsion and Fibrocell sport a Zacks Rank  1  Strong Buy   Editas carries a Zacks Rank  2  Buy   You can see  Celsion s loss estimates narrowed from 94 cents to 78 cents for both 2019 and 2020 over the past 60 days Fibrocell s loss estimates narrowed from  2 68 to  1 15 for 2019 and from  2 55 to 97 cents for 2020 over the past 60 days Editas  loss estimates narrowed from  2 74 to  2 68 for 2019 and from  3 10 to  3 01 for 2020 over the past 60 days Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 7 stocks to watch  The report is only available for a limited time ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/spectrum-pharma-sppi-q1-earnings-lag-estimates-revenues-nil-200420118,200420118
1356,222871,CLSN,Sarepta  SRPT  Q1 Earnings Top Estimates  Exondys 51 Sales Up,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   incurred an adjusted loss of 75 cents per share in the first quarter of 2019  wider than the year ago loss of 28 cents per share  The wider year over year loss can be primarily attributed to a significant rise in operating expenses  Notably  the adjusted figure excluded one time items  depreciation   amortization expenses  interest expenses  and income tax benefit  Including all these items  the company incurred a loss of  1 07 per share compared with a loss of 55 cents in the year ago quarter  The loss was much narrower than the Zacks Consensus Estimate of a loss of  2 05 Meanwhile  Sarepta s Exondys 51   the first Duchenne muscular dystrophy   DMD   treatment to gain approval in the United States   continued with its strong performance  Sarepta recorded total revenues of  87 million  up 3 1  sequentially  entirely from the sale of Exondys 51  The top line was in line with the Zacks Consensus Estimate  In the prior year quarter  Sarepta had earned revenues of  64 6 million Duchenne muscular dystrophy is a rare muscular degenerative disease that mostly affects boys and can be fatal before patients turn 30 Shares of Sarepta were up 2 4  in pre market trading on May 9 following earnings release  The stock has gained 6 2  so far this year compared with the  s rise of 3 1  Operating ExpensesAdjusted research and development  R D  expenses totaled  81 4 million in the first quarter  up 88  year over year  The upside was primarily driven by ramp up of manufacturing activities for micro dystrophin program and initiation of certain post marketing studies for Exondys 51  The metric was partially offset by lower cost related to clinical studies evaluating Exondys 51 and golodirsen Adjusted selling  general   administrative  SG A  expenses were  47 8 million  up 41 8  year over year  Higher costs related to the global commercial expansion of its products and increased personnel expenses led to the uptick Cost of sales was also higher  reflecting higher inventory costs due to rising demand for Exondys 51 and royalty payments to BioMarin   NASDAQ BMRN    per the terms of the 2017 settlement and license agreements related to the latter s exon skipping technology used in DMD therapies Exon Skipping Pipeline UpdateSarepta is building its DMD pipeline  which will enhance its approved drug portfolio  The pipeline candidates  on approval  will be eligible to treat a larger patient population than Exondys 51  Currently  the company has about eight exon skipping pipeline candidates  which can treat 75 80  of DMD patients  Sarepta is also developing gene therapies for treating DMD In February  the FDA granted priority review to the new drug application   NDA   seeking accelerated approval for golodirsen  A decision is expected by mid August An approval to golodirsen NDA is likely to boost Sarepta s top line as the drug will increase the eligible DMD patient population by 8  Moreover  Sarepta is planning to submit a new drug application for its second DMD candidate  casimersen  by mid 2019  if study data confirms preclinical dystrophin expression  The company is planning to have three approved exon skipping drugs   including Exondys 51  golodirsen and casimersen   in its portfolio by the first quarter of 2020  following which it expects the eligible patient population to double In March  the company  positive interim data from the phase III ESSENCE study evaluating casimersen in DMD patients  Data showed that the candidate led to statistically significant mean increase of dystrophin protein production compared to baseline and placebo New Gene Therapy UpdateEarlier this week  Sarepta expanded its gene therapy pipeline to six candidates by signing an agreement with the Research Institute at Nationwide Children s Hospital  Per the agreement  the company gained rights to the hospital s gene therapy candidate  calpain 3  which is being evaluated for Limb girdle muscular dystrophy   LGMD   type 2A In February  Sarepta announced positive preliminary results from an early stage study evaluating gene therapy  MY 101 for treating LGMD  Data showed robust protein expression in muscles  which was significantly higher than the pre defined threshold value Sarepta Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Other Stocks to ConsiderSarepta currently carries a Zacks Rank  2  Buy  A couple of other top ranked stocks in the pharmaceutical sector includeCelsion Corporation   NASDAQ CLSN   and Fibrocell Science Inc   NASDAQ FCSC    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  Celsion s loss estimates narrowed from 94 cents to 78 cents for 2019 as well as for 2020 over the past 60 days Fibrocell s loss estimates narrowed from  2 68 to  1 15 for 2019 and from  2 55 to 97 cents for 2020 over the past 60 days This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-q1-earnings-top-estimates-exondys-51-sales-up-200419587,200419587
